Business Wire

Planview Delivers Industry-First Convergence of Portfolio Management, Agile Planning, and Value Stream Management

Share

Planview, the leading platform for digital connected work from portfolio planning to delivery, today announced a first-to-market offering–Digital Product Insights–that combines portfolio management and agile planning with delivery insights from value stream management (VSM) and objectives & key results (OKRs). Planview is the first and only company in the market to provide organizations with connected, data-driven visibility across the lifecycle of a strategy, effectively connecting software delivery to the business with a comprehensive view of impact and objective performance. This announcement delivers on Planview’s digital connected work mission by giving companies a concrete way to break down organizational silos with a single view of shared metrics and business outcome insights.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230724740437/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Connect software delivery to business outcomes with visibility across the lifecycle of your strategy – from planning to delivery to business impact. Use proactive and predictive value stream management insights to pivot plans and drive on-time delivery (Graphic: Business Wire)

“For far too long, a black box has existed between business strategies and how software is delivered against them,” said Razat Gaurav, CEO of Planview. “To thrive in today’s fast-paced environment, the entire C-Suite, from CEO to CFO to CTO, need shared, real-time, actionable data regarding the health of their entire organization’s business and digital transformation initiatives. Planview delivers an innovative way to leverage predictive delivery insights and sentiment details and put them back into portfolio, value stream, and team plans, helping organizations create faster feedback loops that yield better decisions and deliver better outcomes—ultimately shining a light on that black box.”

One of the key data inputs into the new Digital Product Insights is AI powered sentiment analysis, which crawls comments for positive, negative or neutral language to provide a holistic view of plan performance, to further support proactive, data-driven decision making and confident delivery predictability. Connected, multi-level objectives and key results are another critical data source, providing end-to-end organizational goal alignment embedded inside the solution for context to the strategy, planning and work happening within the organization.

“The combination of strategy, planning, and delivery insights in a single view is instrumental to driving digital transformation success and customer value,” said Mik Kersten, CTO, Planview and author of the bestselling book Project to Product: How to Survi ve and Thrive in the Age of Digital Disruption with the Flow Framework. “With this offering we are providing a better way to connect portfolio management and agile planning to the delivery engine, giving organizations a powerful, data-rich consolidated view into how their delivery teams are impacting business outcomes. The typical reporting within a software organization is retroactive, reactive, and disjointed. To truly pivot and make capacity planning and funding decisions, organizations need to be able to continuously feed delivery and process insights into the portfolios, value streams, and teams as work is happening.”

“This new capability gives us a way to do that, using delivery feedback to pivot plans, processes, and capacity to yield more value and efficiency, while also ensuring organizational alignment with shared objectives and key results. These are things you just can’t do when your systems, teams, and tools are disconnected and out of alignment,” he added.

Complementing this functionality, Planview is announcing two additional innovations focused on delivering data-driven visibility to further strengthen the connection between software delivery and business outcomes.

  • Planview Universal Connector, available through select Planview partners, extends connectivity across the enterprise toolchain, allowing organizations to continue their use of in-house or industry specific applications as part of their value delivery, while seamlessly connecting into the entire Planview ecosystem. This addition promotes efficiency and value continuity, further enhancing Planview’s ability to provide holistic, data-driven visibility across the software delivery lifecycle.
  • Roadmaps for Teams help organizations translate plans into visual timelines for achieving their business outcomes and completing deliverables. Used in conjunction with Digital Product Insights, interactive roadmaps aid in driving and aligning product direction and expectations throughout delivery.

Planview is a Leader in the 2023 Gartner® Magic QuadrantTM for Strategic Portfolio Management. The company was also named a leader in The Forrester Wave™: Value Stream Management, Q4 2022.

For more information about how Planview is driving Portfolio Management, Agile Planning, and Value Stream Management convergence, attend the company’s webinar Connect Portfolio Management and Agile Planning to Your Delivery Engine with Value Stream Management on Aug. 17 at 9:30 a.m. CT. Register here.

Gartner, Magic Quadrant for Strategic Portfolio Management, Anthony Henderson, Daniel Stang, John Spaeth, Shailesh Muvera, Woojin Choi, 25 April 2023. GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Planview

Planview has one mission: to build the future of connected work, from ideas to impact. Planview helps organizations accelerate the achievement of what matters most, supporting our customers from need to speed, from passion to progress, and from overhead to optimization. Our connected platform of solutions underpins the business and digital transformations of more than 4,500 customers globally, including 59 of the Fortune 100. Planview empowers enterprises to improve time-to-market and predictability, increase efficiency to unlock capacity, and ensure their most strategic initiatives deliver the desired business outcomes.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations for Planview
Natalie Reina
Director of Corp Comms
956-878-9176
natalie.reina@planview.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye